Esthesioneuroblastoma differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 16: Line 16:
*Pituitary macroadenoma
*Pituitary macroadenoma


*The following list describes the outcome of each of these diseases with various immunohistochemical tests.
 
*Distinguishing esthesioneuroblastomas from the other tumors is of paramount importance because the tumors respond differently to various treatment modalities.
 
 
The following list describes the outcome of each of these diseases with various immunohistochemical tests.
Distinguishing esthesioneuroblastomas from the other tumors is of paramount importance because the tumors respond differently to various treatment modalities.


{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center
Line 71: Line 74:
|-
|-
|}
|}


==References==
==References==

Revision as of 15:07, 26 January 2016

Esthesioneuroblastoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Esthesioneuroblastoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Esthesioneuroblastoma differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Esthesioneuroblastoma differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Esthesioneuroblastoma differential diagnosis

CDC on Esthesioneuroblastoma differential diagnosis

Esthesioneuroblastoma differential diagnosis in the news

Blogs on Esthesioneuroblastoma differential diagnosis

Directions to Hospitals Treating Esthesioneuroblastoma

Risk calculators and risk factors for Esthesioneuroblastoma differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]

Overview

Esthesioneuroblastoma must be differentiated from other tumors with similar histological appearance, such as lymphoma, Ewing sarcoma, melanoma, olfactory/ other [rhabdomyosarcoma or Merkel cell carcinoma], neuroblastoma, and small cell carcinoma.

Differential Diagnosis

The differential diagnosis of esthesioneuroblastoma includes the following:

  • Olfactory neuroepithelioma
  • Olfactory groove meningioma/haemangiopericytoma
  • Sinonasal carcinoma (including SCC, minor salivary gland adenocarcinoma)
  • Rhabdomyosarcoma
  • Melanoma metastases
  • Lymphoma
  • Chordoma
  • Juvenile nasopharyngeal angiofibroma
  • Pituitary macroadenoma



The following list describes the outcome of each of these diseases with various immunohistochemical tests. Distinguishing esthesioneuroblastomas from the other tumors is of paramount importance because the tumors respond differently to various treatment modalities.

Disease Immunohistochemical Tests
Esthesioneuroblastoma
  • Esthesioneuroblastomas stain positive for neuron-specific enolase and/or S-100 protein,
  • While the stain usually is negative for desmin, cytokeratin, vimentin, actin, glial fibrillary acidic protein, UMB 45, and the common leukocytic antigen.
  • For difficult cases, electron microscopy can be useful.
  • Common features are small, round neuroepithelial cells arranged in rosette or pseudorosette patterns, separated by fibrous elements. Rosettes consist of a central space ringed by columnar cells with radially oriented nuclei.
Lymphoma
  • Lymphoma can be excluded when the majority of tumor cells are negative for CD45 (the remaining positive cells demonstrate no atypical immunophenotype).
Ewing sarcoma
  • Ewing sarcoma is positive for MIC2/CD99 gene products that result from an 11;22 translocation
Melanoma
  • Melanoma can be identified using a combination of immunohistochemical markers: HMB-45, MART-1/Melan-A, and S-100.
  • S-100 is expressed in more than 95% of melanomas.
Rhabdomyosarcoma
  • Rhabdomyosarcoma displays a loss of chromosome 11 and stains positive for desmin (expressed in 95%), muscle-specific actin, and myoglobin.
Merkel cell carcinoma
  • Markel cell carcinoma stains positively for low-molecular-weight cytokeratin 20 and NSE.
Neuroblastoma
  • Neuroblastoma often stains positive for NSE, synaptophysin, Leu7, and neurofilament protein.
  • Elevated serum catecholamines are also suggestive of neuroblastoma.
Small cell carcinomas
  • Small cell carcinomas stain positively for chromogranin, NSE, and synaptophysin (presynaptic nerve cell vesicles). Most small cell carcinomas are positive for TTF-1.

References

Template:Central nervous system tumors

Template:WH Template:WS